Andelyn to Apply AAV Curator® Platform to Support Evolyra's IND-Enabling Studies and GMP Manufacturing for Clinical Trials
COLUMBUS, Ohio, April 14, 2026 /PRNewswire/ -- Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced today a partnership with Evolyra Therapeutics to manufacture clinical-grade AAV gene therapies for treating types 2C and 2D Limb-Girdle Muscular Dystrophies (LGMDs). Andelyn will utilize its proprietary AAV Curator® Platform to support Evolyra's gene therapy development programs targeting LGMDR3 and LGMDR5, two severe forms of muscular dystrophy for which there is currently no cure.
Evolyra is developing next-generation gene therapies using a proprietary muscle-targeting AAV vector (AAVMYO2). This vector substantially improves skeletal muscle expression and significantly decreases liver toxicity compared to first-generation vectors. The company has achieved successful preclinical results, demonstrating complete protein expression and muscle restoration in animal models.
"Evolyra exemplifies the kind of transformative science we are eager to support," said Matt Niloff, Chief Commercial Officer at Andelyn Biosciences. "Their innovative approach to treating LGMDs with an AAV gene therapy aligns with our mission to accelerate access to life-changing treatments for patients with rare and ultra-rare diseases. We are very honored to help bring this breakthrough therapy to the patients who need it most."
"We appreciate the partnership and commitment from Andelyn Biosciences. Their platform will allow a seamless transition between the different phases of our therapeutic development, ultimately accelerating our ability to bring these therapies to individuals living with LGMD as quickly as possible," said Nicholas Johnson, MD, CEO of Evolyra Therapeutics.
This manufacturing partnership supports Evolyra's development timeline, which includes IND submission in the second half of 2026, followed by Phase I/II clinical trials. Evolyra recently completed a $5 million seed funding round and is currently raising a $20 million Series A to advance these programs.
LGMDs comprise about 32 rare genetic muscle disorders that lead to progressive muscle weakness and wasting, often beginning in the hip and shoulder muscles. The current global market for LGMD treatments exceeds $100 billion and impacts over 580,000 patients worldwide. Evolyra's initial programs focus on LGMDR3 and LGMDR5, which represent an $11 billion market with approximately 20,000 patients worldwide.
Andelyn's AAV Curator® Platform offers flexible, high-quality manufacturing solutions tailored for rare disease therapies, helping biotech companies to advance from preclinical stages to clinical trials with speed and precision.
About Andelyn Biosciences, Inc.
Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization, and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn's deep scientific expertise has resulted in the production of cGMP material for more than 500 clinical batches and 85 global clinical trials. Operating out of its development and manufacturing facilities in Columbus, Ohio, Andelyn supports its clients who are developing cell and gene therapies from concept through plasmid engineering and manufacturing, process and analytical development, and cGMP clinical and commercial manufacturing. Andelyn can accelerate programs and deliver high-quality products by developing and manufacturing processes on its configurable, data-driven AAV Curator® Platform or tech transfer in an established client program. Capabilities include cGMP manufacturing for suspension processes up to 2,000 liters and adherent processes. A rigorous quality system, regulatory support, and supply chain vertical integration further advantages clients in bringing their critical therapies to market. For more information, please visit andelynbio.com and follow on LinkedIn.
About Evolyra Therapeutics
Evolyra Therapeutics, headquartered in Richmond, Virginia, is dedicated to developing transformative gene therapies for rare neuromuscular diseases, with an initial focus on the limb-girdle muscular dystrophies (LGMD). The company is advancing a next-generation gene therapy platform built on muscle-targeting adeno-associated virus (AAV) vectors designed to deliver full-length functional genes directly to skeletal muscle while minimizing off-target effects such as liver toxicity. This differentiated approach aims to overcome safety and efficacy limitations observed in earlier gene therapy programs. Evolyra is initially targeting LGMD subtypes 2C and 2D—progressive, currently untreatable conditions that lead to severe muscle degeneration and reduced quality of life—but envisions a scalable and modular platform strategy, enabling the development of full gene replacement therapies across more than 20 LGMD subtypes and potentially other genetic diseases. Evolyra integrates clinical expertise, translational research, and patient-driven data through collaborations with academic leaders and global patient consortia to accelerate development and improve trial readiness. Founded by physicians, scientists, and biotech leaders, Evolyra Therapeutics emphasizes a patient-centric model focused on safety, precision, and speed. For more information, please visit https://evolyratherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/andelyn-biosciences-partners-with-evolyra-therapeutics-for-the-clinical-manufacturing-of-gene-therapies-for-the-treatment-of-limb-girdle-muscular-dystrophies-302740699.html
SOURCE Andelyn Biosciences
